Cargando…

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies

Toll-like receptors (TLRs) are a family of pattern recognition receptors and part of the first line of defense against invading microbes. In humans, we know of 10 different TLRs, which are expressed to varying degrees in immune cell subsets. Engaging TLRs through their specific ligands leads to acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinsen, Janne Tegder, Gunst, Jesper Damsgaard, Højen, Jesper Falkesgaard, Tolstrup, Martin, Søgaard, Ole Schmeltz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300204/ https://www.ncbi.nlm.nih.gov/pubmed/32595636 http://dx.doi.org/10.3389/fimmu.2020.01112

Ejemplares similares

TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure
por: Hvilsom, Caroline Thue, et al.
Publicado: (2021)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses
por: Brinkmann, Christel Rothe, et al.
Publicado: (2018)

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
por: Winckelmann, Anni A., et al.
Publicado: (2013)

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy
por: Lende, Stine Sofie Frank, et al.
Publicado: (2022)

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
por: Macedo, Amanda B., et al.
Publicado: (2019)

Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson’s disease
por: Amo-Aparicio, Jesus, et al.
Publicado: (2023)

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues
por: Denton, Paul W., et al.
Publicado: (2019)

Effect of Age on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients
por: Cham, Lamin B., et al.
Publicado: (2021)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
por: Rasmussen, Thomas Aagaard, et al.
Publicado: (2013)

Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals
por: Bukh, Anne Roslev, et al.
Publicado: (2011)

Immunomodulation with IL-7 and IL-15 in HIV-1 infection
por: Gunst, Jesper D., et al.
Publicado: (2023)

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals
por: Winckelmann, Anni, et al.
Publicado: (2018)

Editorial: COVID-19: From bedside to follow-up
por: Gunst, Jesper Damsgaard, et al.
Publicado: (2023)

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
por: Gunst, Jesper D, et al.
Publicado: (2019)

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
por: Chakraborty, Samik, et al.
Publicado: (2023)

SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
por: Nielsen, Stine SF, et al.
Publicado: (2021)

Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants
por: Kumar, Sudeep, et al.
Publicado: (2019)

Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1
por: Cham, Lamin B., et al.
Publicado: (2023)

Persistent Symptoms in Patients Recovering From COVID-19 in Denmark
por: Leth, Steffen, et al.
Publicado: (2021)

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
por: Offersen, Rasmus, et al.
Publicado: (2012)

Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques
por: Yan, Xianglei, et al.
Publicado: (2023)

Use of Toll-Like Receptor Agonists to Induce Ectopic Lymphoid Structures in Myasthenia Gravis Mouse Models
por: Robinet, Marieke, et al.
Publicado: (2017)

Modeling Kick-Kill Strategies toward HIV Cure
por: Hernandez-Vargas, Esteban A.
Publicado: (2017)

Toll-Like Receptor 8 Agonist Strengthens the Protective Efficacy of ESAT-6 Immunization to Mycobacterium tuberculosis Infection
por: Tang, Jun, et al.
Publicado: (2018)

SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
por: Vibholm, Line K, et al.
Publicado: (2021)

The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells
por: Guo, Xueheng, et al.
Publicado: (2017)

Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B
por: Wildum, Steffen, et al.
Publicado: (2022)

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial
por: Gunst, Jesper D., et al.
Publicado: (2023)

The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome
por: Petes, Carlene, et al.
Publicado: (2017)

Editorial: Lymph Node T Cell Dynamics and Novel Strategies for HIV Cure
por: Petrovas, Constantinos, et al.
Publicado: (2018)

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials
por: Rasmussen, Thomas A., et al.
Publicado: (2013)

Age-Dependent Changes of Adipokine and Cytokine Secretion From Rat Adipose Tissue by Endogenous and Exogenous Toll-Like Receptor Agonists
por: Peek, Verena, et al.
Publicado: (2020)

Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization
por: Klastrup, Vibeke, et al.
Publicado: (2022)

Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to the Yersinia pestis Plague rF1V Vaccine
por: Biryukov, Sergei, et al.
Publicado: (2021)

BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists
por: Noé, Andrés, et al.
Publicado: (2023)

Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: author's response
por: Søgaard, Ole Schmeltz
Publicado: (2022)

Toll-Like Receptors of Deuterostome Invertebrates
por: Satake, Honoo, et al.
Publicado: (2012)

Toll-Like Receptors and Skin Cancer
por: Burns, Erin M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ered47q6fpcljep3p4f0m3d5t0